Plasma biomarkers of acute GVHD and nonrelapse mortality: Predictive value of measurements before GVHD onset and treatment

Blood

Volumn 126, Issue 1, 2015, Pages 113-120

  McDonald, George B ^a,b   Tabellini, Laura ^a   Storer, Barry E ^a,b   Lawler, Richard L ^a   Martin, Paul J ^a,b   Hansen, John A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; BIOLOGICAL MARKER; BUSULFAN; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; GANCICLOVIR; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; BLOOD LEVEL; CALCULATION; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY; ACUTE DISEASE; ADVERSE EFFECTS; BLOOD; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; TIME FACTOR; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; BIOMARKERS; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84937792055     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-636753     Document Type: Article

References (26)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
2. Levine JE, Braun TM, Harris AC, et al; for the Blood and Marrow Transplant Clinical Trials Network. A prognostic score for acute graftversus-host disease based on biomarkers: A multicenter study. Lancet Haematol. 2015;2(1): e21-e29.
3. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2):749-755.
4. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day 15 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107(10):4177-4181.
5. Castilla-Llorente C, Martin PJ, McDonald GB, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966-971.
6. Xhaard A, Rocha V, Bueno B, et al. Steroidrefractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant. 2012;18(3):406-413.
7. Paczesny S. Discovery and validation of graftversus-host disease biomarkers. Blood. 2013; 121(4):585-594.
8. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graftversus-host disease and death. N Engl J Med. 2013;369(6):529-539.
9. Ponce DM, Hilden P, Mumaw C, et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2015;125(1): 199-205.
10. Rezvani AR, Storer BE, Storb RF, et al. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1594-1601.
11. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
12. Hansen JA, Hanash SM, Tabellini L, et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(9):1323-1330.
13. Holtan SG, Verneris MR, Schultz KR, et al. Circulating angiogenic factors associated with response and survival in patients with acute Graftversus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant. 2015; 21(6):1029-1036.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
15. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13): 2888-2894.
16. Martin PJ, Furlong T, Rowley SD, et al. Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(6): 922-929.
17. Malone FR, Leisenring WM, Storer BE, et al. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2007;40(8):765-772.
18. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102(2):756-762.
19. MacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
20. Rodriguez-Otero P, Porcher R, Peffault de Latour R, et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 2012;119(24):5909-5917.
21. Abraham J, Janin A, Gornet JM, et al. Clinical severity scores in gastrointestinal graft-versushost disease. Transplantation. 2014;97(9): 965-971.
22. Levine JE, Huber E, Hammer ST, et al. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood. 2013;122(8): 1505-1509.
23. Socié G, Mary J-Y, Lemann M, et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood. 2004;103(1):50-57.
24. Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology. 1980;78(4):764-771.
25. DiCarlo J, Agarwal-Hashmi R, Shah A, et al. Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2014; 20(3):361-369.
26. Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host diseasefree, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015; 125(8):1333-1338.